HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fructose Promotes Cytoprotection in Melanoma Tumors and Resistance to Immunotherapy.

Abstract
Checkpoint blockade immunotherapy relies on the empowerment of the immune system to fight cancer. Why some patients fail to achieve durable clinical responses is not well understood, but unique individual factors such as diet, obesity, and related metabolic syndrome could play a role. The link between obesity and patient outcomes remains controversial and has been mired by conflicting reports and limited mechanistic insight. We addressed this in a C57BL/6 mouse model of diet-induced obesity using a Western diet high in both fats and sugars. Obese mice bearing B16 melanoma or MC38 carcinoma tumors had impaired immune responses to immunotherapy and a reduced capacity to control tumor progression. Unexpectedly, these compromised therapeutic outcomes were independent of body mass and, instead, were directly attributed to dietary fructose. Melanoma tumors in mice on the high-fructose diet were resistant to immunotherapy and showed increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1). This increase in HO-1 protein was recapitulated in human A375 melanoma cells exposed to fructose in culture. Induced expression of HO-1 shielded tumor cells from immune-mediated killing and was critical for resistance to checkpoint blockade immunotherapy, which could be overcome in vivo using a small-molecule inhibitor of HO-1. This study reveals dietary fructose as a driver of tumor immune evasion, identifying HO-1 expression as a mechanism of resistance and a promising molecular target for combination cancer immunotherapy.See article by Khojandi et al., p. 214.
AuthorsLindsey M Kuehm, Niloufar Khojandi, Alexander Piening, Lauryn E Klevorn, Simone C Geraud, Nicole R McLaughlin, Kristine Griffett, Thomas P Burris, Kelly D Pyles, Afton M Nelson, Mary L Preuss, Kevin A Bockerstett, Maureen J Donlin, Kyle S McCommis, Richard J DiPaolo, Ryan M Teague
JournalCancer immunology research (Cancer Immunol Res) Vol. 9 Issue 2 Pg. 227-238 (02 2021) ISSN: 2326-6074 [Electronic] United States
PMID33023966 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright©2020 American Association for Cancer Research.
Chemical References
  • Antineoplastic Agents, Immunological
  • Fructose
  • Heme Oxygenase-1
Topics
  • Animals
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Carcinoma
  • Cell Line, Tumor
  • Cytoprotection
  • Drug Resistance, Neoplasm
  • Female
  • Fructose (metabolism)
  • Heme Oxygenase-1 (metabolism)
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms (drug therapy, metabolism)
  • Tumor Escape

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: